Järelepärimine

Saatja: "Karbus, Kairit" <[email protected]> Saaja: "Ravimiamet" <[email protected]> Teema: Küsimus/Ravimiregister ja ATC-kood - RINVOQ Kuupäev: 2024-04-03 06:05 Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada. Tere! Märkasime, et ravimil RINVOQ (upadatsitiniib) on ravimiregistris ja SPC-s erinev ATC kood. Kas oleks palun võimalik seda kontrollida. Ette tänades Kairit Karbus Heade soovidega / Kind regards, _____ KAIRIT KARBUS Regulatory Affairs Manager Abbvie Estonia AbbVie OÜ Rävala pst.4 10145 Tallinn Estonia CELL +372 5088264 EMAIL <mailto:[email protected]> [email protected] This communication may contain information that is proprietary, confidential, or exempt from disclosure. If you are not the intended recipient, please note that any other dissemination, distribution, use or copying of this communication is strictly prohibited. Anyone who receives this message in error should notify the sender immediately by telephone or by return e-mail and delete it from his or her computer. _____